Good news for parents in China! A new weapon in the fight against respiratory syncytial virus (RSV) has been approved, promising to protect infants from this common and potentially dangerous illness. A First Line of Defense: AstraZeneca and Sanofi announced the approval of Beyfortus, a long-acting monoclonal antibody, for preventing RSV lower respiratory tract infections...
